The rapid developing of CRISPR/Cas mediated gene-editing technologies is an immensely powerful research tool with remarkable promise to revolutionize the future therapy for genetic diseases, cancer, and sensitive nucleic acid detection, diagnosis of infectious diseases and beyond. Despite the increasing maturity of CRISPR-Cas9 technology, its safety and efficiency are important concerns requiring comprehensive studies. Clinical translation of the CRISPR-Cas9 system is hampered by off-target alterations. In infectious disease diagnosis, metagenomic Next Generation Sequencing (mNGS) has emerged as a promising technology for global detection of pathogens in clinical samples. However, standard methods are often not sensitive enough to detect critical sequences like those responsible for antimicrobial resistance. Novel approaches (DASH and FLASH) based on the programmability of the CRISPR/Cas9 system to increase coverage of desired organisms and genes can result in increased assay sensitivity.
Getting More from your MiSeq with DASH and FLASH
Emily Crawford, PhD, Chan Zuckerberg Biohub, San Francisco, CA USA
Assessing Unintended Off-Target Mutations Caused by Cas9 and Other Gene Editing Enzymes
Vikram Pattanayak, MD, PhD, Massachusetts General Hospital, Boston, MA, USA
Objectives:
- Describe the basic functions of the CRISPR/Cas9 system.
- Discuss the benefits and limitations of metagenomic Next Generation Sequencing (mNGS) for infectious disease diagnostics.
- Discuss the application of CRISPR technology as a diagnostic tool for infectious diseases.
Duration: 1.50 hr
Recording Date: November 7, 2019
CME/CMLE credit: 1.50 hr
Last day to purchase course and CE claim credit: December 24, 2022
